One To Watch
Accord BioPharma
Company Overview
A U.S. specialty biosimilar division of Accord Healthcare — itself part of Intas Pharmaceuticals — targeting 20 approved biosimilars across oncology, immunology, and supportive care by 2030. Accord BioPharma operates as the dedicated American commercialization arm for a portfolio built on Intas's global regulatory infrastructure, which spans more than 10,000 registered medications across 85 countries. Two FDA approvals in the first half of 2026 signal an organization that has moved from pipeline-building to active market entry.
Headquarters and Global Presence
Accord BioPharma is headquartered in Parsippany, New Jersey, operating as the U.S. specialty division of Accord Healthcare. Its commercial and regulatory reach draws on Intas Pharmaceuticals' established presence across the EU and U.S. markets.
Founding and History
Accord BioPharma was established as the U.S. specialty unit of Accord Healthcare, the branded and specialty arm of Ahmedabad-based Intas Pharmaceuticals, one of India's larger privately held pharma groups. The division was structured specifically to commercialize biosimilars in the American market, a strategic priority for Intas as originator biologics face patent expiry. Its 2026 FDA approvals — for FILKRI in February and IMMGOLIS in May — mark the transition from development entity to commercial operator.
Therapy Areas and Focus
The company's biosimilar portfolio spans three verticals: immunology (anti-TNF and related targets), oncology supportive care (colony-stimulating factors), and critical/supportive care. Immunology carries the heaviest pipeline weight, with seven biosimilars in development globally against that category alone. The strategic logic is straightforward — anti-TNF biologics such as golimumab and adalimumab represent multi-billion-dollar annual spend, and biosimilar uptake in the U.S. immunology segment, while lagging Europe, is accelerating under IRA-era formulary pressure.
Technology Platforms and Modalities
Accord BioPharma does not operate an internal biologics discovery engine; instead, it sources biosimilar candidates through exclusive U.S. licensing agreements with development partners, then leverages Intas's global manufacturing and regulatory infrastructure to support FDA submissions. This asset-in-licensing model concentrates risk at the commercialization rather than the development stage. The approach allows Accord to move at scale — 20 U.S. approvals by 2030 is an ambitious target — while relying on partners with established analytical comparability packages rather than building them from scratch.
Key Pipeline and Programs
IMMGOLIS (golimumab-sldi) and IMMGOLIS INTRI received FDA approval in May 2026 as the first biosimilars to Simponi (subcutaneous) and Simponi Aria (intravenous), respectively. Both reference Johnson & Johnson's golimumab, a TNF-alpha inhibitor approved across rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, and ulcerative colitis — a combined U.S. market exceeding $1 billion annually. IMMGOLIS was developed by Bio-Thera Solutions as BAT2506, with Accord holding exclusive U.S. commercialization rights under a licensing agreement. Janssen filed BPCIA patent infringement proceedings against Bio-Thera and Accord in March 2026, a standard originator maneuver that will shape the commercial launch timeline.
FILKRI (filgrastim-laha) is Accord's biosimilar to Amgen's NEUPOGEN (filgrastim), approved by the FDA in February 2026. Filgrastim is a granulocyte colony-stimulating factor used to reduce infection risk from chemotherapy-induced neutropenia — a high-volume supportive care indication with established biosimilar competition. FILKRI expands Accord's non-immunology footprint and provides near-term revenue footing as the golimumab launch navigates patent litigation.
Beyond these approved assets, Accord's global immunology pipeline includes seven biosimilar programs, with additional candidates in varying stages of development for the U.S. market as part of the 2030 target.
Recent Developments
The FDA approved FILKRI (filgrastim-laha) in February 2026, followed by IMMGOLIS and IMMGOLIS INTRI in May 2026 — two approvals in four months representing a step-change in the company's U.S. commercial standing. The golimumab approval is particularly notable as the first-ever biosimilar designation for either Simponi formulation. In March 2026, Janssen initiated BPCIA patent litigation against Bio-Thera and Accord over BAT2506, a proceeding that could delay or complicate the IMMGOLIS commercial launch depending on patent dance outcomes.
Key Personnel
Chrys Kokino serves as President of Accord BioPharma, leading the U.S. specialty division's commercialization strategy and partnership development. Accord BioPharma operates within the broader Accord Healthcare and Intas Pharmaceuticals leadership structure, drawing on the group's global regulatory and commercial expertise.
Strategic Partnerships
The most consequential partnership on record is an exclusive U.S. licensing and commercialization agreement with Bio-Thera Solutions for BAT2506 (IMMGOLIS), giving Accord sole rights to the first golimumab biosimilar in the American market. Intas Pharmaceuticals' network of regulatory approvals across 85 countries provides the broader infrastructure underpinning Accord's U.S. pipeline strategy. The company's model — licensing in development-stage candidates and deploying Intas's manufacturing scale — suggests additional partnership agreements are likely as it pursues the 20-biosimilar target.
FAQ Section
Accord BioPharma functions as the U.S. commercial execution arm for biosimilar assets developed or licensed within the Intas group, which has registered more than 10,000 medications across 85 countries. That global regulatory footprint means Accord can bring candidates to FDA submission with established comparability data from EU and other markets already in hand. The structure allows aggressive scale — a target of 20 U.S. biosimilar approvals by 2030 — without building a domestic development organization from the ground up.
Golimumab (Simponi/Simponi Aria) is a TNF-alpha inhibitor with U.S. annual revenues exceeding $1 billion, approved across rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, and ulcerative colitis. Until IMMGOLIS's FDA approval in May 2026, no biosimilar had been cleared for either formulation, leaving the reference market entirely insulated from price competition. First-mover status in that space — assuming patent litigation with Janssen is resolved — carries meaningful commercial weight for formulary positioning and market share capture.
Rather than building internal biologics manufacturing, Accord BioPharma licenses development-stage candidates from specialist partners and routes them through Intas's global manufacturing and regulatory infrastructure. This separates the development risk from the commercialization risk, concentrating Accord's exposure on market access and payer strategy — areas where the Intas group has established U.S. experience. The model also enables a broader portfolio ambition (20 approvals by 2030) than most pure-play biosimilar developers can sustain independently.
IMMGOLIS (golimumab-sldi) and IMMGOLIS INTRI received FDA approval in May 2026 as the first biosimilars referencing Simponi and Simponi Aria, respectively. In March 2026 — before the approvals — Janssen commenced BPCIA patent infringement proceedings against developer Bio-Thera Solutions and Accord, the standard originator litigation play under the Biologics Price Competition and Innovation Act. The outcome and timeline of that patent dance will be the critical variable determining when IMMGOLIS can move from approval to active commercial launch.
Immunology carries the greatest weight, with seven biosimilar programs in development globally against that category — anti-TNF and related biologics that collectively represent some of the highest-spend reference products in U.S. specialty pharmacy. Oncology supportive care is the second pillar, exemplified by the FILKRI filgrastim approval in February 2026, targeting chemotherapy-induced neutropenia. Critical and supportive care rounds out the three-vertical strategy, providing diversification across payer channels and market dynamics.
Two FDA approvals in the first four months of 2026 — FILKRI in February and IMMGOLIS in May — mark the formal transition from pipeline-building entity to commercial operator. FILKRI competes in an established filgrastim biosimilar market where uptake is driven by formulary contracting and oncology practice agreements. The more consequential near-term milestone is the resolution of Janssen's BPCIA patent litigation, which will set the commercial launch date for IMMGOLIS and determine first-mover advantage in the golimumab biosimilar segment.
Several developments will determine whether Accord's 2026 momentum translates into durable market position:
Latest Accord BioPharma News
Today's issue
| Headless Content Management with Blaze